Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The price of Repligen Corp (NASDAQ: RGEN) closed at $125.61 in the last session, up 3.23% from day before closing price of $121.68. In other words, the price has increased by $3.23 from its previous closing price. On the day, 0.56 million shares were traded. RGEN stock price reached its highest trading level at $125.9 during the session, while it also had its lowest trading level at $121.99.
Ratios:
We take a closer look at RGEN’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.97 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 66.70. For the most recent quarter (mrq), Quick Ratio is recorded 7.32 and its Current Ratio is at 8.59. In the meantime, Its Debt-to-Equity ratio is 0.33 whereas as Long-Term Debt/Eq ratio is at 0.32.
On June 24, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $150.Barclays initiated its Overweight rating on June 24, 2025, with a $150 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 10 ’25 when Hunt Anthony sold 29,111 shares for $120.52 per share. The transaction valued at 3,508,389 led to the insider holds 100,743 shares of the business.
Hunt Anthony bought 29,111 shares of RGEN for $3,508,378 on Sep 10 ’25. On Aug 08 ’25, another insider, Madaus Martin D, who serves as the Director of the company, bought 1,800 shares for $112.13 each. As a result, the insider paid 201,830 and bolstered with 1,800 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RGEN now has a Market Capitalization of 7066519040 and an Enterprise Value of 7043728384. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.49 while its Price-to-Book (P/B) ratio in mrq is 3.43. Its current Enterprise Value per Revenue stands at 10.451 whereas that against EBITDA is 55.701.
Stock Price History:
The Beta on a monthly basis for RGEN is 1.07, which has changed by -0.1559602 over the last 52 weeks, in comparison to a change of 0.1529237 over the same period for the S&P500. Over the past 52 weeks, RGEN has reached a high of $182.52, while it has fallen to a 52-week low of $102.96. The 50-Day Moving Average of the stock is 4.59%, while the 200-Day Moving Average is calculated to be -7.11%.
Shares Statistics:
According to the various share statistics, RGEN traded on average about 824.44K shares per day over the past 3-months and 861570 shares per day over the past 10 days. A total of 56.25M shares are outstanding, with a floating share count of 53.16M. Insiders hold about 5.51% of the company’s shares, while institutions hold 97.92% stake in the company. Shares short for RGEN as of 1757894400 were 3541604 with a Short Ratio of 4.30, compared to 1755216000 on 3898921. Therefore, it implies a Short% of Shares Outstanding of 3541604 and a Short% of Float of 8.49.
Earnings Estimates
The stock of Repligen Corp (RGEN) is currently in the spotlight, with 17.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is $0.5, with high estimates of $0.57 and low estimates of $0.45.
Analysts are recommending an EPS of between $1.77 and $1.65 for the fiscal current year, implying an average EPS of $1.68. EPS for the following year is $2.18, with 17.0 analysts recommending between $2.38 and $1.87.
Revenue Estimates
According to 18 analysts, . The current quarter’s revenue is expected to be $181.72M. It ranges from a high estimate of $185.7M to a low estimate of $178.03M. As of . The current estimate, Repligen Corp’s year-ago sales were $154.87MFor the next quarter, 18 analysts are estimating revenue of $193.15M. There is a high estimate of $200.5M for the next quarter, whereas the lowest estimate is $185.04M.
A total of 19 analysts have provided revenue estimates for RGEN’s current fiscal year. The highest revenue estimate was $734.8M, while the lowest revenue estimate was $716.62M, resulting in an average revenue estimate of $726.17M. In the same quarter a year ago, actual revenue was $634.44MBased on 18 analysts’ estimates, the company’s revenue will be $827.2M in the next fiscal year. The high estimate is $850M and the low estimate is $794.14M.
